LENZ lets eligible patients get VIZZ online, with home delivery
LENZ Therapeutics has launched a new telehealth prescribing option for its VIZZ aceclidine ophthalmic solution, designed to treat presbyopia. This platform, accessible via VIZZ.com, connects patients with licensed eye care providers for online evaluations, e-pharmacy prescription fulfillment, and home delivery. The initiative is being promoted through a national TV and digital campaign featuring Sarah Jessica Parker, aiming to enhance awareness, access, and adoption of VIZZ among the 128 million Americans with presbyopia.
LENZ Therapeutics Launches Telehealth Access for VIZZ Alongside National TV Campaign
LENZ Therapeutics has launched telehealth accessibility for its presbyopia treatment, VIZZ (aceclidine ophthalmic solution) 1.44%, allowing patients to receive online evaluations, e-pharmacy prescription fulfillment, and home delivery. This initiative coincides with a national advertising campaign featuring Sarah Jessica Parker to boost awareness and adoption among the 128 million Americans affected by presbyopia. While this expansion improves convenience and outreach, potential negatives include reliance on independent eye care professionals for evaluations and reported adverse reactions like instillation site irritation and dim vision, which could impact consumer confidence.
LENZ - LENZ Therapeutics Inc Options
This article provides comprehensive financial data for LENZ Therapeutics Inc. (LENZ), including its last closing price, market capitalization, income, sales, and various financial ratios. It also details insider and institutional ownership, stock performance metrics, and analyst recommendations.
Director departure and audit committee change at LENZ Therapeutics (NASDAQ: LENZ)
LENZ Therapeutics announced changes to its Board of Directors and Audit Committee following the resignation of director Zach Scheiner on June 30, 2026. Scheiner's departure was not due to any dispute, and the Board subsequently reduced its size to six members. Additionally, Jeff George was appointed to the Audit Committee, which now includes Shelley Thunen, Frederic Guerard, and Jeff George.
Price to sales forward of LENZ Therapeutics, Inc. – NASDAQ:LENZ
This article focuses on the "Price to sales forward" metric for LENZ Therapeutics, Inc. (NASDAQ: LENZ). It appears to be a financial data snippet from TradingView, providing an overview of the company's stock performance. The content includes general market information and links to various TradingView features but lacks detailed financial analysis or specific numerical data for the price-to-sales forward ratio.
Price to book forward of LENZ Therapeutics, Inc. – NASDAQ:LENZ
This article provides a brief financial update on LENZ Therapeutics, Inc. (NASDAQ: LENZ), specifically focusing on its price-to-book forward ratio. The content indicates the market is currently closed, with no trades, and offers information on the company's financials, news, and other market data points accessible through TradingView.
Enterprise value to revenue forward of LENZ Therapeutics, Inc. – NASDAQ:LENZ
This article provides financial information for LENZ Therapeutics, Inc. (NASDAQ: LENZ), specifically focusing on its enterprise value to revenue forward. The content appears to be a financial snapshot from TradingView, detailing various data points and market information relevant to the company.
Price to earnings forward of LENZ Therapeutics, Inc. – NASDAQ:LENZ
This article provides the "Price to earnings forward" metric for LENZ Therapeutics, Inc. (NASDAQ: LENZ). It's presented within the context of TradingView's financial data offerings for the company. The page focuses on a specific financial data point rather than a detailed analytical report.
LENZ Therapeutics, Inc.(NasdaqGS:LENZ) added to Russell Microcap Value Benchmark Index
LENZ Therapeutics, Inc. (NasdaqGS:LENZ), a biopharmaceutical company focused on developing treatments for presbyopia, has been added to the Russell Microcap Value Benchmark Index. This news follows a period of significant activity for the company, including recent license agreements, earnings reports, and analyst rating changes. The article also provides a company profile, financial data, and analyst consensus.
LENZ Therapeutics, Inc.(NasdaqGS: LENZ) added to Russell 2000 Value Benchmark
LENZ Therapeutics, Inc. (NasdaqGS: LENZ) has been added to the Russell 2000 Value Benchmark Index. This news follows several recent updates for the biopharmaceutical company, including its addition to the Russell Microcap Value Benchmark and an exclusive licensing agreement for its VIZZ product in Australia and New Zealand. The company develops aceclidine-based eye drops for presbyopia.
LENZ Therapeutics, Inc.(NasdaqGS:LENZ) dropped from Russell Small Cap Comp Growth Benchmark
LENZ Therapeutics, Inc. (NasdaqGS:LENZ) has been removed from the Russell Small Cap Comp Growth Benchmark. This news follows a previous report that the company was also dropped from the Russell 3000 Growth Benchmark. The company, which is a pre-commercial stage biopharmaceutical firm focusing on an aceclidine-based eye drop for presbyopia, has recently seen its stock performance decline significantly.
Millennium Group reports 1.60M-share (5.1%) LENZ stake (LENZ)
Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have reported a shared voting and dispositive power over 1,603,512 shares, or 5.1%, of LENZ Therapeutics, Inc. Common Stock. This disclosure was made via a Schedule 13G filing, indicating a passive investment. The shares are held by entities managed by Millennium Management LLC and its affiliates, as detailed in a joint filing agreement.
LENZ Therapeutics, Inc. Actuals & Estimates (NASDAQ:LENZ)
This article provides an overview of LENZ Therapeutics, Inc. (NASDAQ: LENZ) stock performance, financial data, and analyst estimates. It includes current stock price, historical highs and lows, market capitalization, volatility, and upcoming earnings report details. The company's financials for the last quarter, including earnings per share and revenue, are also highlighted.
LENZ Therapeutics Eye Drug Profile Supports Blockbuster Opportunity: Analyst
LENZ Therapeutics has signed an exclusive licensing and commercialization agreement with Arrotex Pharmaceuticals for its FDA-approved eye drop therapy, VIZZ, targeting presbyopia in Australia and New Zealand. This marks LENZ's fifth such international partnership, with an analyst from William Blair highlighting its potential as a blockbuster drug due to its best-in-class profile and differentiated efficacy, despite early launch phases in the U.S.
LENZ Therapeutics, Inc. and Arrotex Pharmaceuticals Pty Ltd. Announce Exclusive License and Commercialization Agreement for VIZZ in Australia and New Zealand
LENZ Therapeutics, Inc. has announced an exclusive license and commercialization agreement with Arrotex Pharmaceuticals Pty Ltd. for its presbyopia treatment, VIZZ, in Australia and New Zealand. LENZ Therapeutics will receive an upfront payment and a significant share of gross profit from product sales, while Arrotex Pharmaceuticals gains exclusive commercialization rights for VIZZ in these regions. The agreement expands the availability of VIZZ, an aceclidine-based eye drop for near vision improvement, into new markets.
LENZ licenses presbyopia drug VIZZ to Arrotex for Australia, NZ By Investing.com
LENZ Therapeutics has granted Arrotex Pharmaceuticals exclusive rights to register and commercialize its presbyopia drug VIZZ in Australia and New Zealand. LENZ will receive an upfront payment and profit share from sales of VIZZ, a once-daily eye drop that received FDA approval in July 2025. Despite this expansion, LENZ shares are trading near their 52-week low, and analyst ratings have been adjusted due to slower-than-expected sales.
LENZ Therapeutics and Arrotex Pharmaceuticals Announce Exclusive License and Commercialization Agreement for VIZZ™ in Australia and New Zealand
LENZ Therapeutics and Arrotex Pharmaceuticals have entered into an exclusive license and commercialization agreement for VIZZ™ eye drops in Australia and New Zealand. This partnership will see Arrotex, Australia’s largest pharmaceutical company, register and commercialize VIZZ, LENZ's FDA-approved aceclidine-based eye drop for presbyopia. LENZ will receive an upfront payment and a significant profit share from product sales, expanding its global commercial footprint for this transformative presbyopia therapy.
LENZ Therapeutics signs exclusive VIZZ deal for Australia and New Zealand
LENZ Therapeutics (NASDAQ:LENZ) has finalized an exclusive licensing and commercialization agreement with Arrotex Pharmaceuticals for its presbyopia treatment, VIZZ, in Australia and New Zealand. This partnership provides LENZ with an upfront payment and a significant share of gross margin profit, marking its fifth ex-US commercialization deal for the FDA-approved eye drop. VIZZ, the first and only FDA-approved aceclidine-based eye drop for presbyopia, was approved in July 2025 and launched in the US in October 2025.
LENZ licenses presbyopia drug VIZZ to Arrotex for Australia, NZ
LENZ Therapeutics, Inc. has entered into an exclusive license and commercialization agreement with Arrotex Pharmaceuticals Pty Ltd. for its presbyopia drug, VIZZ, in Australia and New Zealand. LENZ will receive an upfront payment and a profit share from sales of VIZZ, a once-daily eye drop that was approved by the U.S. FDA in July 2025. This marks LENZ's fifth international commercialization partnership for VIZZ, despite the company's shares struggling near a 52-week low.
LENZ Therapeutics and Arrotex Pharmaceuticals Announce
LENZ Therapeutics and Arrotex Pharmaceuticals have entered into an exclusive license and commercialization agreement for VIZZ™ in Australia and New Zealand. This agreement will allow Arrotex to register and commercialize VIZZ, LENZ's FDA-approved aceclidine-based eye drop for presbyopia, in these regions. LENZ will receive an upfront payment and a significant profit share from product sales, expanding VIZZ's global reach.
LENZ Therapeutics (NasdaqGS:LENZ) Stock Forecast & Analyst Predictions
LENZ Therapeutics (NasdaqGS:LENZ) is forecast to grow earnings and revenue significantly, but is expected to remain unprofitable for the next three years, with projected negative return on equity. Recent analyst revisions show decreased revenue forecasts and increased loss projections, alongside multiple price target reductions. The company has submitted Marketing Authorization Applications for its presbyopia treatment, VIZZ, in the UK and Europe, following FDA approval in the US, but faces challenges with market uptake and high cash burn.
LENZ expands VIZZ beyond the U.S. with Australia, NZ deal
LENZ Therapeutics has partnered with Arrotex Pharmaceuticals for the exclusive license and commercialization of VIZZ, their FDA-approved presbyopia eye drop, in Australia and New Zealand. This agreement is LENZ's fifth ex-U.S. commercialization deal for VIZZ and includes an upfront payment and a significant profit share for LENZ. VIZZ, an aceclidine ophthalmic solution, was approved in the US in July 2025 and launched commercially in October 2025.
LENZ Therapeutics Inc (LENZ) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of LENZ Therapeutics Inc (LENZ), stating its current valuation score is 6.79, ranking it 297 out of 388 in the Biotechnology & Medical Research industry. It highlights the company's P/E ratio is -1.74, significantly below its recent high, and notes that relevant data for P/B, P/S, and P/CF ratios have not been disclosed by the company. The article focuses primarily on these valuation metrics and LENZ's industry ranking, without further detailed financial insights due to missing data.
LENZ Therapeutics Inc (LENZ) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of LENZ Therapeutics Inc (LENZ), focusing on its support and resistance levels, key indicators, and moving averages. The stock's current price momentum score is 6.40, ranking it 263 out of 388 in its industry, and it is trading between a resistance level of 7.79 and a support level of 5.59. Various technical indicators, including MACD, RSI, and StochRSI, show mostly neutral to sell signals, while all moving averages from MA5 to MA200 indicate sell signals.
LENZ (NASDAQ: LENZ) director awarded 22,100 stock options at $6.63 strike
LENZ Therapeutics director Kimberlee C. Drapkin was granted 22,100 stock options with an exercise price of $6.63 per share, expiring on June 15, 2036. This compensation-related award vests entirely on the earlier of June 15, 2027, or the next annual stockholders' meeting, provided Drapkin continues to serve as an Outside Director. Following this grant, Drapkin directly holds 22,100 options.
RA Capital-linked entities receive 22,100 LENZ (LENZ) options via director grant
LENZ Therapeutics has reported a grant of 22,100 stock options to entities linked with RA Capital, through director Dr. Scheiner. These options have an exercise price of $6.63 per share and expire on June 15, 2036. The shares will vest on the earlier of June 15, 2027, or the next annual stockholder meeting, contingent on Dr. Scheiner's continued service as an Outside Director, with any net proceeds funnelled to RA Capital to offset advisory fees.
Director-linked entities at LENZ Therapeutics (LENZ) granted 22,100 stock options
Entities linked to a director at LENZ Therapeutics, specifically RA Capital Management, have been granted 22,100 stock options with an exercise price of $6.63 per share and an expiration date of June 15, 2036. The options are compensation-related and will vest earlier of June 15, 2027, or the next annual stockholder meeting, provided the reporting person remains an Outside Director. The director disclaims beneficial ownership, as any net proceeds from the options will offset advisory fees owed by RA Capital's investment vehicles.
LENZ Therapeutics grants 22,100 options to director | LENZ Insider Trading
LENZ Therapeutics director George Jeffrey P. was granted 22,100 stock options with an exercise price of $6.63 per share, expiring on June 15, 2036. The options will fully vest on the earlier of June 15, 2027, or the next annual stockholders' meeting, provided he continues as an Outside Director. This transaction is classified as a compensation grant rather than a market purchase.
Director at LENZ Therapeutics (NASDAQ: LENZ) receives 22,100 options
Frederic Guerard, a director at LENZ Therapeutics (NASDAQ: LENZ), has been granted 22,100 stock options. These options have an exercise price of $6.63 per share and are set to expire on June 15, 2036. The options will vest completely on the earlier of June 15, 2027, or the date of the next annual stockholders' meeting, provided Guerard continues his role as an Outside Director.
LENZ Therapeutics (LENZ) grants director 22,100 stock options at $6.63
LENZ Therapeutics director Shelley B. Thunen was granted 22,100 stock options at an exercise price of $6.63 per share, expiring on June 15, 2036. The options will vest 100% on the earlier of June 15, 2027, or the next annual stockholder meeting, contingent on her continued service as an Outside Director. This transaction is classified as a compensation award rather than an open-market purchase.
Lenz Therapeutics shareholders elect directors and ratify auditor at annual meeting
Lenz Therapeutics (NASDAQ:LENZ) held its 2026 annual meeting where shareholders elected three Class II directors and ratified Ernst & Young LLP as its independent auditor. Despite a 77% stock decline over the past year, InvestingPro analysis suggests the company may be undervalued. The company also recently reported first-quarter 2026 financial results with $1.9 million in net revenues and a net loss of $41.5 million, leading to adjusted price targets from analysts.
Lenz Therapeutics shareholders elect directors and ratify auditor at annual meeting
Lenz Therapeutics shareholders held their 2026 annual meeting, electing three Class II directors and ratifying Ernst & Young LLP as their independent registered public accounting firm for the fiscal year ending December 31, 2026. The company's stock has declined 77% over the past year, though InvestingPro analysis suggests it may be undervalued. In related news, the company reported Q1 2026 net revenues of $1.9 million, a net loss of $41.5 million, and has seen varied analyst ratings following the broad launch of its product VIZZ.
[8-K] LENZ Therapeutics, Inc. Reports Material Event
LENZ Therapeutics, Inc. reported the results of its 2026 annual stockholder meeting held on June 12, 2026. Stockholders elected three Class II directors—Evert Schimmelpennink, Jeff George, and Shelley Thunen—to serve until the 2029 annual meeting and also ratified the appointment of Ernst & Young LLP as their independent registered public accounting firm for the fiscal year ending December 31, 2026. Of the 31,354,394 common shares outstanding, 24,442,068 shares were represented at the meeting.
LENZ Technical Analysis & Stock Price Forecast
This article provides a technical analysis and stock price forecast for LENZ Therapeutics Inc (LENZ), concluding with a "Strong Sell" consensus based on various indicators. It details momentum indicators like RSI and MACD, support and resistance levels, and different moving averages, all contributing to the bearish outlook for the stock.
LENZ Therapeutics (LENZ) Stock Price, News & Analysis
LENZ Therapeutics (NASDAQ: LENZ) stock is currently trading at $6.46, representing a 60.6% decrease from its early 2026 price of $16.00. The biopharmaceutical company focuses on developing therapies for presbyopia, with its LNZ100 and LNZ101 product candidates in Phase III clinical trials. Analysts have a "Moderate Buy" consensus rating with a price target of $29.80, suggesting a significant upside potential of 373.1%.
LENZ Therapeutics adds China partner for presbyopia drug VIZZ
LENZ Therapeutics has partnered with Everest Medicines to develop and commercialize VIZZ (LNZ100), its presbyopia drug, in Greater China. An NDA for LNZ100 was submitted in China in September 2025, with approval anticipated in early 2027. This agreement allows LENZ to leverage Everest's established presence in the Chinese market while retaining rights in other regions.
LENZ Therapeutics adds China partner for presbyopia drug VIZZ
LENZ Therapeutics has partnered with Everest Medicines to develop and commercialize VIZZ (LNZ100), a presbyopia drug, in Greater China. Everest Medicines will handle the drug's development and commercialization, with approval of the New Drug Application in China anticipated in the first quarter of 2027. This sublicense ensures a local specialist will launch the product in a market LENZ cannot directly serve.
LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China
LENZ Therapeutics announced that Everest Medicines has acquired the rights to develop and commercialize VIZZ® (LNZ100), an aceclidine-based eye drop for presbyopia, in Greater China. An New Drug Application for LNZ100 was submitted in China in September 2025, with approval anticipated in Q1 2027. LENZ Therapeutics is eligible to receive up to $85.0 million in regulatory and sales milestones, plus tiered royalties on net sales, from Everest Medicines as part of the agreement.
LENZ Therapeutics and Everest Medicines Form Strategic Partnership for Development and Commercialization of VIZZ in Greater China
LENZ Therapeutics has partnered with Everest Medicines for the development and commercialization of VIZZ (aceclidine ophthalmic solution) for presbyopia in Greater China. Everest Medicines acquired the rights from Corxel Pharmaceuticals, with LENZ eligible to receive up to $85 million in milestones and royalties. The New Drug Application for VIZZ in China was submitted in September 2025, with approval anticipated in Q1 2027, aiming to provide a non-invasive treatment option for presbyopia.
LENZ - LENZ Therapeutics - a high risk high reward small cap biotech stock
This article evaluates LENZ Therapeutics, highlighting it as a high-risk, high-reward small-cap biotech stock. The company's primary product, VIZZ, is an FDA-approved eye drop for presbyopia (farsightedness) slated for October 2025 distribution. The author presents a bullish thesis based on VIZZ's market potential, estimating significant revenue with even a small adoption rate, while also cautioning about the risks associated with a single-product company, small market cap, and high short interest.
LENZ Therapeutics to Participate in Upcoming Investor Conferences
LENZ Therapeutics, Inc. announced its participation in three upcoming investor conferences in June 2026: the William Blair 46th Annual Growth Stock Conference, the Jefferies Global Healthcare Conference, and the Goldman Sachs 47th Annual Global Healthcare Conference. The company, focused on commercializing VIZZ® for presbyopia treatment, will hold 1x1 investor meetings at these events. VIZZ® is the first and only FDA-approved aceclidine-based eye drop for presbyopia.
LENZ Therapeutics to Participate in Upcoming Investor Conferences
LENZ Therapeutics, a pharmaceutical company, announced its upcoming participation in several investor conferences in June 2026. The company will be attending the William Blair 46th Annual Growth Stock Conference, the 2026 Jefferies Global Healthcare Conference, and the Goldman Sachs 47th Annual Global Healthcare Conference to hold 1x1 investor meetings. LENZ Therapeutics is focused on the commercialization of VIZZ®, an FDA-approved eye drop for presbyopia.
Eye drop company LENZ heads to three investor conferences in June
LENZ Therapeutics, a pharmaceutical company focusing on VIZZ eye drops for presbyopia, announced its participation in three investor conferences in June 2026. Management will host 1x1 investor meetings at the William Blair 46th Annual Growth Stock Conference, the Jefferies Global Healthcare Conference, and the Goldman Sachs 47th Annual Global Healthcare Conference. This news led to a moderate positive market reaction, with LENZ stock gaining 2.65%.
Users
This article provides detailed stock information for LENZ Therapeutics, Inc. (LENZ), including its current quote, performance metrics, and a list of recent news and press releases. It covers financial results, corporate highlights, product submissions for approval, and investor alerts from various sources. The stock closed at 7.340 with a slight uptick, despite significant year-to-date and long-term declines.
Some LENZ Therapeutics, Inc. (NASDAQ:LENZ) Analysts Just Made A Major Cut To Next Year's Estimates
Analysts have significantly revised down their forecasts for LENZ Therapeutics, Inc. (NASDAQ:LENZ) for 2026, cutting revenue estimates and increasing projected losses per share. The new consensus from seven analysts anticipates revenues of US$19 million and a loss of US$4.50 per share, leading to a 19% reduction in the consensus price target to US$32.00. This downgrade suggests growing caution among investors regarding the company's future valuation and performance.
Some LENZ Therapeutics, Inc. (NASDAQ:LENZ) Analysts Just Made A Major Cut To Next Year's Estimates
Analysts have significantly revised down their forecasts for LENZ Therapeutics, Inc. for the coming year. Revenue estimates for 2026 were cut to US$19 million, reflecting a 9.3% reduction, and per-share losses are now expected to reach US$4.50. This downgrade has also led to a 19% reduction in the consensus price target to US$32.00.
Earnings Update: LENZ Therapeutics, Inc. (NASDAQ:LENZ) Just Reported And Analysts Are Trimming Their Forecasts
LENZ Therapeutics, Inc. (NASDAQ:LENZ) recently reported quarterly results, with revenues beating expectations but statutory losses per share increasing significantly. Following these results, analysts have made serious cuts to their revenue outlook for 2026, forecasting a 4.5% reduction in revenue and a 29% increase in losses per share. This led to a 15% drop in the average price target, reflecting concerns about the company's future valuation and performance.
LENZ Therapeutics, Inc. (LENZ) reports Q4 loss, misses revenue estimates
LENZ Therapeutics, Inc. (LENZ) announced a wider-than-expected loss for the fourth quarter, reporting a loss of 69 cents per share. The company also reported no revenue for the period, falling short of analyst estimates. This performance suggests challenges for LENZ Therapeutics as it moves forward.
Earnings Update: LENZ Therapeutics, Inc. (NASDAQ:LENZ) Just Reported And Analysts Are Trimming Their Forecasts
LENZ Therapeutics, Inc. reported quarterly results showing revenues of US$1.9m, beating expectations, but statutory losses per share increased to US$1.32. Following these results, analysts have significantly cut revenue forecasts for 2026 to US$20.0m and increased loss per share estimates to US$4.47, leading to a 15% reduction in the average price target to US$33.71. The adjustment reflects concerns about future performance despite exceeding revenue expectations this quarter.
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
LENZ Therapeutics' shares have suffered a significant drop following its latest quarterly results, leading analysts to revise their earnings forecasts downwards. The consensus estimates suggest a substantial increase in losses for the current financial year and potentially the next, with revenue expectations also seeing a decrease. Despite the share price slump, one analyst has recently reiterated a "Buy" rating, indicating some continued optimism for the company.
